Incyte Corporation (NASDAQ: INCY) is a Healthcare company (Biotechnology) with a market capitalization of $24.7B. The Maz Rating grades it against the other companies in its sector.
Incyte Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $120.97, Incyte Corporation trades at 57.6x trailing earnings, 4.1x sales and 4.4x book value, with an EV/EBITDA of 24.5. Over the last twelve months it generated about $6.0B of revenue and $428M of net income. It runs a gross margin of 92.7%, an operating margin of 11.6% and a net margin of 6.7%. It shows return on equity of 7.1%, return on invested capital of 6.0% and a free cash flow yield of 2.8%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 3.84. Over the past 52 weeks the share price ranged from $89.25 to $132.60, with a beta of 0.78.
Incyte Corporation does not currently pay a dividend.
45 Wall Street analyst ratings cover the stock: 24 Buy, 20 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Incyte Corporation (INCY) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 16.2% / 30% · Interest income / Revenue 2.07% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 15.9% / 33% · Receivables / Mkt Cap (36m) 5.09% / 49% · Interest income / Revenue 2.07% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 15.9% / 33.33% · Receivables / Mkt Cap (24m) 5.09% / 33.33% · Interest income / Revenue 2.07% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 54.3% / 33.33% · Receivables / Avg Assets (4Q) 15.1% / 33.33% · Interest income / Revenue 2.07% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 52.9% / 33.33% · (Cash+Recv) / Total Assets 69.9% / 33.33% · Interest income / Revenue 2.07% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Incyte Corporation (INCY) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Incyte Corporation is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 2.07% of each dividend: Incyte Corporation's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.